Drug Database
Back to search

Belgium· BE-AMP-SAM124232-00

Feiba 500 U

A faktor viii-inhibitor bypass aktivität - feiba product containing anti-inhibitor coagulant complex, registered in Belgium by Baxalta Innovations. The same ATC class is registered in 10 of our 19 countries.

ATC B02BD03

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedFeiba 500 UATCB02BD03REGISTER NO.BE-AMP-SAM124232-00PACKS LISTED1CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about anti-inhibitor coagulant complexAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Faktor viii-inhibitor bypass aktivität - feiba is registered in 10 of 19 countries.

Countries holding a registration under ATC B02BD03 (faktor viii-inhibitor bypass aktivität - feiba), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 6 of them publish a price we can compare per daily dose
Search faktor viii-inhibitor bypass aktivität - feiba products by name

Faktor viii-inhibitor bypass aktivität - feiba · ATC B02BD03

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Anti-Inhibitor Coagulant Complex
Manufacturer
Baxalta Innovations
Country
Belgium (BE)
ATC code
B02BD03
ATC class
Faktor VIII-Inhibitor Bypass Aktivität - FEIBA
Defined daily dose
7 TSD, E
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 1

  • be_apb
    1286954

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

5 interactions on record for faktor viii-inhibitor bypass aktivität - feiba.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check faktor viii-inhibitor bypass aktivität - feiba against other medicinesHow interaction checks work

Faktor viii-inhibitor bypass aktivität - feiba · interactions on record

5 records

  • 4 severe
  • 1 moderate

Most severe, free to view

  • Aminocaproic acidB02AA01severe
  • Tranexamic acidB02AA02severe
  • AprotininB02AB01severe
  • EmicizumabB02BX06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Faktor viii-inhibitor bypass aktivität - feiba in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All faktor viii-inhibitor bypass aktivität - feiba products

Authorised across Europe · EMA

The same active substance is authorised in 27 EEA countries. Names it is sold under:

  • Austria · Feiba
  • Bulgaria · Фейба
  • Cyprus · Feiba
  • Czechia · Feiba
  • Germany · Feiba
  • Denmark · Feiba
  • Estonia · Feiba
  • Spain · Feiba
  • Finland · Feiba
  • France · Feiba
  • United Kingdom (Northern Ireland) · Feiba
  • Greece · Feiba
  • Croatia · Feiba
  • Hungary · Feiba Nf
  • Ireland · Feiba
  • Italy · Feiba
  • Lithuania · Feiba
  • Latvia · Feiba
  • Malta · Feiba
  • Netherlands · Feiba
  • Norway · Feiba
  • Poland · Feiba Nf
  • Portugal · Feiba Nf
  • Romania · Feiba
  • Sweden · Feiba
  • Slovenia · Feiba
  • Slovakia · Feiba

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e8a10140-40ee-4de3-ae62-43afc7c6830b
GET /v1/drugs/e8a10140-40ee-4de3-ae62-43afc7c6830b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder and solvent for solution for injection",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Feiba 500 U",
  "name_fr": "Feiba 500 U",
  "name_nl": "Feiba 500 U",
  "amp_code": "SAM124232-00",
  "strengths": [
    "500.0000",
    "160.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Anti-Inhibitor Coagulant Complex",
    "Sodium Chloride"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Factor Viii Inhibitor Bypassing Activity",
  "authorisation_numbers": [
    "BE124232"
  ]
}
API referenceMCP serverPlans

See everything about faktor viii-inhibitor bypass aktivität - feiba.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console